Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations

Perrigo’s third-quarter 2026 Core adjusted EPS fell 9.0% year over year to $0.61, while Core net sales declined 1.7% to $908 million and adjusted operating margin contracted 210 bps to 14.3%; reported diluted EPS was a loss of $0.10. The company lowered its full-year outlook, citing the Infant Formula divestiture, more measured retailer inventory positioning and continued softness in Europe; it expects a $275 million–$375 million impairment loss in Q4 from measuring the business as held for sale. The announced Infant Formula sale provides $40 million upfront and up to $135 million tied to sales milestones through 2030; Perrigo also paid $40 million in third-quarter dividends.

Analysis

The key issue is whether portfolio simplification can outrun deterioration in the remaining earnings engine. Core sales softness is accompanied by weaker operating income in both Self Care and Specialty Care, so share gains are not yet translating into profitable growth. Retailer inventory restraint may shift demand across quarters, but it also leaves PRGO exposed to a weak cough-and-cold season and production under-absorption if sell-through disappoints. Increased promotion and advertising further limit near-term operating leverage.

The Infant Formula exit is strategically coherent but offers little immediate balance-sheet relief: only part of the stated consideration is upfront cash, with the rest contingent on milestones, against substantial debt and roughly 4x guided net leverage. The expected impairment is noncash, but should not distract from the more relevant question—whether recurring cash generation can support deleveraging and dividends. The very low adjusted tax rate also cushions EPS this quarter and is not a dependable operating offset. Adjusted results exclude substantial items, including litigation-related expense; investors should track cash conversion and reported results alongside adjusted margins.

Near term, the call’s detail on retailer orders and seasonal sell-through can drive the stock more than the divestiture headline. Over 1–3 months, the next evidence is holiday-season demand, margin recovery, and progress on the Oral Care strategic review. Over 6–18 months, execution and debt reduction matter more than portfolio labels. A contrarian risk to a bearish stance is that inventory normalization plus cost actions produces a sharp earnings rebound; market-share gains could then support better mix and operating leverage. Conversely, persistent European softness or failure to convert share into volume and margin would undermine the simplification thesis.

Key Decisions for Investors

• Maintain an underweight bias to PRGO; consider a tactical short only after any divestiture-driven relief rally, rather than chasing weakness into the cough-and-cold season. The risk/reward improves if retailer orders remain cautious; no price target is warranted from the supplied information.
• Do not assign material near-term deleveraging value to the full Infant Formula consideration: monitor closing conditions, upfront cash actually received, contingent milestone terms, and the use of proceeds. The sale’s thesis is falsified if leverage does not trend below management’s roughly 4x level as cash flow normalizes.
• Track quarterly organic Core sales, adjusted operating margin, operating cash flow conversion, and retailer inventory/sell-through. A return to positive organic growth with sequential margin stabilization would weaken the short thesis; continued margin erosion despite share gains would strengthen it.
• Treat the Oral Care review as a catalyst, not a valuation premium: verify transaction terms and whether proceeds are directed to debt reduction before underwriting incremental value.